If things go as per plan, in a few months, the US Food and Drug Administration (FDA) will deliberate on the first-of-its-kind CRISPR-based gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia.
Having made significant advances in a relatively short period of time, , and this month’s cover story takes a look at the major players in this field and the big events that could break through this year.
Artificial intelligence (AI) continues to be in the news, and as pharma companies invest more to make sure they’re ahead of the game, . We also explore
Also in this issue, we stay on the diversity beat and explore how trials can be more inclusive when it comes to .
Read for all this and insights, and
You can also subscribe here to receive email notifications when a new issue is available.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
